Leflunomide Should Be Taken Daily, Not Five Times Weekly
Leflunomide must be administered as 20 mg daily for rheumatoid arthritis, not five times per week. The FDA-approved dosing regimen is unequivocal: 20 mg per day following an optional loading dose 1. This daily dosing schedule is the only regimen validated for efficacy and safety in major clinical trials and endorsed by international guidelines.
Why Daily Dosing Is Required
The pharmacokinetics and clinical trial data for leflunomide are based entirely on daily administration:
- FDA approval and all pivotal trials (US301, MN301/303/305, MN302/304) used 20 mg daily dosing after loading 1
- EULAR 2017 guidelines recommend leflunomide at 20 mg/day (without loading dose) as an alternative to methotrexate for rheumatoid arthritis 2
- The active metabolite (M1) has a long half-life requiring consistent daily dosing to maintain therapeutic levels
What About Weekly Dosing Studies?
While some small research studies explored weekly leflunomide dosing (50-100 mg once weekly), these have critical limitations that prevent clinical recommendation:
- A 2016 study compared 50 mg weekly vs 10 mg daily (not the standard 20 mg daily dose), showing similar efficacy only in mild-to-moderate early RA 3
- This study was open-label with high risk of bias and used a suboptimal comparator dose 4
- Small pilot studies (2002-2004) with 100 mg weekly showed delayed onset of benefit compared to daily dosing 5, 6
- No weekly regimen has FDA approval or guideline endorsement
Critical Safety Concern
Taking leflunomide only 5 times weekly (skipping 2 days) would result in:
- Subtherapeutic drug levels on non-dosing days
- Unpredictable disease control
- No safety data supporting this irregular schedule
- Potential for treatment failure and disease progression with joint damage
The Bottom Line
There is no validated five-times-weekly leflunomide regimen. If daily dosing is problematic due to side effects, the appropriate response is dose reduction to 10 mg daily (though less effective) or switching to an alternative DMARD like sulfasalazine 2. Arbitrary schedule modifications without evidence risk treatment failure and irreversible joint damage in rheumatoid arthritis.